The artificial intelligence (AI) revolution is here, and it's going to upend the biopharma sector in ways that most investors might not have considered. The end results are impossible to predict with accuracy, but based on what's possible with the AI tools of today, investors could reap tremendous returns from companies that are aggressive with implementing AI into their workflows. 

Specifically, there are at least three ways that AI is going to disrupt biotech stocks in the near term. Let's take a look at them.

Image source: Getty Images.

Continue reading

Source Fool.com